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 1.  Introduction 
 Peripheral nerve injury (PNI) often occurs during trauma 
involving crushing, laceration, ischemia, and stretching of 
the body and its limbs. Despite the robust pro-regenerative 
response of peripheral neurons to injury, functional recovery is 
often unsatisfactory. 
 PNI continues to be a major global health problem with 
signifi cant negative impact on the quality of life of patients. 
 Peripheral nerve injury continues to be a major global health problem that 
can result in debilitating neurological defi cits and neuropathic pain. Current 
state-of-the-art treatment involves reforming the damaged nerve pathway 
using a nerve autograft. Engineered nerve repair conduits can provide an 
alternative to the nerve autograft avoiding the inevitable tissue damage 
caused at the graft donor site. Commercially available nerve repair conduits 
are currently only considered suitable for repairing small nerve lesions; the 
design and performance of engineered conduits requires signifi cant improve-
ments to enable their use for repairing larger nerve defects. 
 Carbon nanotubes (CNTs) are an emerging novel material for biomedical 
applications currently being developed for a range of therapeutic technologies 
including scaffolds for engineering and interfacing with neurological tissues. 
CNTs possess a unique set of physicochemical properties that could be 
useful within nerve repair conduits. This progress report aims to evaluate and 
consolidate the current literature pertinent to CNTs as a biomaterial for sup-
porting peripheral nerve regeneration. The report is presented in the context 
of the state-of-the-art in nerve repair conduit design; outlining how CNTs may 
enhance the performance of next generation peripheral nerve repair conduits. 
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Neurological defi cits can range from tem-
porary sensory and motor impairments, 
to permanent paralysis of entire limbs or 
organs, often accompanied by severe neu-
ropathic pain. Transected nerves can be 
repaired by direct end-to-end suture, but 
when tensionless coaptation is not pos-
sible a nerve autograft must be used to 
bridge the gap between the two ends of the 
damaged nerve. Autografts protect, pro-
mote and guide axon regeneration from 
the proximal injured nerve into the distal 
nerve stump. Despite the success of this 
repair technique the inevitable damage 
caused at the graft donor site including 
loss of sensation, painful neuroma forma-
tion and scarring, makes this treatment far 
from ideal. 
 A variety of bioengineered nerve repair 
conduits (NRCs) have been developed to 
overcome the problems associated with 
nerve autografts. These conduits have 
proven successful for smaller often digital 
nerve lesions however, the nerve autograft 
is still the preferred gold standard treatment for larger nerve 
defects (>30 mm). Improving the performance of current NRCs 
to circumvent the signifi cant side-effects of nerve autografts for 
large nerve lesion repair is consequently an intensely studied 
area of research that has inspired a variety of biomaterial 
approaches including nanomaterial-based strategies. 
 Recent advances in the fi eld of carbon nanotubes (CNTs) 
have instigated a wealth of research into potential nano-
biomaterial applications including supporting and promoting 
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the regeneration of neural tissue. CNTs possess a unique set of 
physicochemical properties that could be useful within NRCs. 
This progress report will evaluate and consolidate the current 
literature pertinent to CNTs as a biomaterial for augmenting 
peripheral nerve repair (PNR) devices. After an introduction to 
peripheral nerve regeneration and existing repair conduits, we 
discuss how CNTs may enhance the performance of next gen-
eration NRCs. 
 2.  Physiology of Peripheral Nerve Regeneration 
 After transection of a peripheral nerve, feedback mechanisms 
from the axon tip induce a set of morphological changes 
termed chromatolysis: swelling of the perikaryon, displacement 
of the nucleus towards the periphery and dissolution of Nissl 
bodies ( Figure  1 ). If the injury is very close to the neuronal cell 
body such as in nerve root avulsion injuries, neuronal apoptosis 
often occurs. If the injury is more distal the expression of a 
plethora of pro-regeneration associated genes (RAGs) enhance 
neuronal survival and prepare the severed axon for regenera-
tion. [ 1 ] The distal end of the axons, cut off from their nutritive 
and regulatory source, the perikaryon, degenerate via a cascade 
of events collectively termed Wallerian degeneration (WD). [ 2 ] 
 The proximal portion of the axon still attached to the peri-
karyon is sealed and begins to regenerate. At the tip of the 
axon, a highly motile structure called the growth cone forms 
and begins to advance into the lesion space. The growth cone 
guides the growing axon by sensing its microenvironment 
via the extension and retraction of fi lopodia and lamellipodia. 
Growth cone migration is governed via contact with extracel-
lular matrix fi bers, Schwann cell tracts and a complex array of 
diffuse and substrate bound molecules. [ 3 ] 
 Schwann cells are key participants in the complex pro-
cesses of WD and axon regeneration in the peripheral 
nervous system. [ 4 ] Granular disintegration of the distal axon 
cytoskeleton induces the de-differentiation and proliferation 
of Schwann cells to an immature phenotype. [ 5 ] Along with 
recruited macrophages, Schwann cells clear the distal nerve 
stump of axonal debris, degraded myelin and growth inhibi-
tory molecules leaving behind fascicles of empty basal lamina 
endoneurial tubes that once surrounded the nerve axons 
(Figure  1 b). 
 Proliferating Schwann cells then assemble into longitudinal 
chains or ‘regeneration tracts’ known as the bands of Büngner 
that line the endoneurial tubes and extend into the lesion gap 
(Figure  1 c). These regeneration tracts provide longitudinal guid-
ance channels for directing axon sprouts from the regenerating 
proximal nerve stump. Gradients of diffusible trophic factors 
produced by Schwann cells and target organs attract growth 
cones towards and along the distal endoneurial tubes. Extracel-
lular matrix (ECM) proteins such as fi bronectin, laminin and 
tenascin produced by Schwann cells enhance the substratum 
for growth cone adherence and guidance. 
 The continual production of growth factors by for example, 
denervated target muscles and Schwann cells, is vital in sus-
taining axon growth during repair of larger nerve lesions. 
Axons regenerate at rates of approximately 1–4 mm per day. [ 6 ] 
Injuries that occur far from the target organ and more proximal 
to the neuronal cell body must regenerate over very long dis-
tances, taking many months to years. Unfortunately, over such 
long periods of time, denervated muscles atrophy, motor end 
plates destabilise and trophic factor expression is downregu-
lated. If reinnervation of motor end plates does not ensue 
within 12 months of injury, functional outcomes are likely to 
be poor. [ 7,8 ] It is therefore vital that nerve repair occurs without 
delay to exploit this narrow window of optimum conditions for 
axon regeneration. 
 3.  Evolution of NRC-design 
 The search for alternatives to the traditional gold standard nerve 
autograft began in the late 19 th century with the introduction 
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of nerve allografts and the construction of the fi rst NRC from 
decalcifi ed bone, arteries and veins. [ 7 ] In the following dec-
ades, clinicians and scientists investigated the effi cacy of 
conduits made from a wide range of bio-
logical and synthetic materials. [ 7,9 ] Findings 
from these studies began to identify the ideal 
design characteristics for NRCs (reviewed 
in de Ruiter et al. and Kehoe et al.). Thus, a 
bespoke NRC should provide structural sup-
port, but be fl exible enough to allow ease of 
surgical insertion and normal anatomical 
movements; it should be permeable to allow 
angiogenesis and the diffusion of essen-
tial molecules, but prevent infi ltration of 
scar tissue. Ideal NRCs should persist long 
enough for regeneration to occur, but also be 
biodegradable to minimise fi brosis, foreign 
body response and constriction of the nerve, 
as well as attenuating the long-term risks of 
infection. Advanced NRCs should be biocom-
patible to prevent infl ammation and meet 
technical requirements for good manufac-
turing production, storage and handling. [ 10,11 ] 
 The design of current commercially avail-
able NRCs consists of a tube or wrap with a 
single hollow lumen into which the two ends 
of the damaged nerve are inserted. A recent 
survey identifi ed eleven conduit devices that 
have secured Food and Drug Administration 
(FDA) approval including the commercially 
available Neurotube (polyglycolic acid), Neu-
rolac (poly ( L -lactic acid-co-caprolactone)); 
Neurogen (collagen type I); NeuroMatrix, 
Neurofl ex (collagen type I) and Salubridge 
(polyvinyl alcohol hydrogel). The Neurotube 
and NeuroGen conduits have achieved the 
most clinical success and are often used to 
repair short digital nerve defects. [ 11 ] These 
conduits support functional recovery com-
parable to autografts however, for lesions 
greater than 3–4 cm their performance often 
falls short with clinicians still preferring the 
nerve autograph. [ 12 ] 
 Since 2007, the AxoGen Avance decellu-
larised allograft has also been available for 
clinical use and has been transplanted into ca 
5000 patients. [ 13 ] A recent clinical trial study 
of 136 nerve repairs supported by the AxoGen 
Avance allograft reported no host immune 
rejection and good functional recovery com-
parable to nerve autografts for lesions up to 
31 mm. [ 14 ] The effi cacy of nerve allografts 
and commercially available NRCs has been 
extensively reviewed in several recent arti-
cles. [ 7,11,15–17 ] With improvements in our 
understanding of nerve repair physiology 
it has become clear that a major limitation 
of commercial NRCs is the lack of a three-
dimensional luminal matrix that can direct 
and promote the growth of advancing regenerating axons. 
 The successful repair of smaller nerve lesions using NRCs 
can be attributed to the formation of a fi brin matrix between 
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 Figure 1.  Wallerian degeneration and regeneration after neurotmesis in the peripheral nervous 
system. a) Peripheral nerve innervating skeletal muscle. Axons are myelinated by Schwann cells and 
surrounded by the basal lamina endoneurial tubes. b) After neurotmesis the proximal tip of the sev-
ered axons are sealed whilst the distal axon and myelin sheaths degenerate. Distally, Schwann cells 
dedifferentiate, proliferate and along with macrophages remove cellular debris and growth inhib-
iting molecules from the lesion and endoneurial tubes. Depending on the proximity of the lesion to 
the neuronal soma, chromatolytic changes may occur within the perikaryon. The denervated muscle 
begins to atrophy. c) The proximal axon sprouts and begins to regenerate into the lesion space. Axon 
regeneration is promoted by soluble growth factors produced by Schwann cells and target muscles. 
Schwann cells line the endoneurial tubes and form the bands of Büngner that guide axon growth. 
d) Axons regenerate along the endoneurial tubes to reinnervate the target muscle. Misalignment or 
aberrant growth of axons and a lack of specifi c topological axon guidance can result in regeneration 
into the wrong endoneurial tube and subsequent innervation of inappropriate targets.
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the nerve stumps within the NRC lumen that facilitates the 
coordinated migration of fi broblasts, Schwann, endothelial and 
perineurial cells to optimise nerve repair ( Figure  2 ). In larger 
lesions, greater than 3 cm for humans and 1 cm for rats, this 
matrix is either unable to form or is unstable hindering the 
migration of Schwann cells and the formation of the bands 
of Büngner. Without a guiding and supporting matrix, axon 
growth through larger lesions is signifi cantly impaired often 
resulting in the formation of painful neuromas and poor func-
tional recovery. [ 18,19 ] Recent advances in our understanding of 
the mechanisms of axon guidance and regeneration coupled 
with technological advances in biological and material engi-
neering promise to bring a new generation of sophisticated, 
biomimetic NRCs with enhanced effi cacy. 
 4.  CNTs: Potential Role in Nerve Repair 
 CNTs are nanoscale tubes of carbon with a structure similar to 
a rolled up sheet of graphene with single or multiple concen-
tric layers. Produced by a variety of techniques, most commonly 
by chemical vapor deposition involving the restructuring of 
carbon atoms using a metal catalyst, their diameters can range 
from 0.4–100 nm and lengths from a few nanometres up to 
0.5 meter. [ 20 ] 
 With a unique set of physiochemical properties, CNTs have 
been dubbed the miracle material of the 21 st century and pro-
moted to have applications in numerous fi elds of science and 
technology. [ 21 ] CNTs are excellent electrical conductors and 
possess nanoscale topographical features. When normalised to 
account for differences in density, CNTs possess a strength that 
is over 50 times greater than steel wire. Extensive research into 
the surface chemistry of CNTs has provided methods to con-
vert their very hydrophobic structure into one that is dispersible 
in aqueous solution and can be functionalised to impart useful 
properties for many applications ( Figure  3 ). [ 22 ] 
 Several research groups have suggested the utilisation of 
CNTs in the fi eld of neuroregeneration and PNR. However, the 
potential roles within NRCs have yet to be fully defi ned. Within 
NRCs, CNT scaffolds could be utilised to enhance axon growth 
rates and anisotropic organization via electrical stimulation and 
contact guidance cues, respectively. They are ideal for providing 
structural reinforcement to biodegradable conduit materials. 
Furthermore, surface functionalisation of CNTs could provide 
a route for the localised administration of growth promoting 
molecules and proteins. 
 4.1.  Directing and Supporting Axonal Growth 
 4.1.1.  The State-of-the-art 
 Structural and topological features formed by the ECM and cell 
surfaces have important roles in guiding axonal growth. This 
is particularly evident during the regeneration of nerve crush 
injuries in comparison to regeneration after nerve transec-
tion. After nerve crush lesions, when the connective tissue of 
the nerve is not breached, axons are able to follow the exact 
pathways of endoneurial tubes back to their original targets 
with 90% accuracy. The precision of regeneration after nerve 
transection injuries is signifi cantly reduced due to loss of align-
ment of axons with their original endoneurial tubes. [ 23 ] The 
importance of including biomimetic directional guidance cues 
within the lumen of NRCs is now well recognised. 
 Progress in tissue engineering and three-dimensional (3D) 
scaffold fabrication techniques have enabled the production of 
biomimetic scaffolds with nano- and micro-features. [ 24 ] These 
scaffolds exploit the ability of sub-cellular physical features to 
control cell behavior and provide topological contact guidance 
cues to direct growth cone migration. [ 3,25 ] Among others, neu-
rite outgrowth in vitro has been directed by nano-imprinted 
grooves and ridges ( Figure  4 a), electrospun fi bers (Figure  4 b), 
printed patterns of ECM proteins, aligned or printed hydro-
gels, aligned Schwann cells and CNT confi gurations including 
arrays, yarns, tubular scaffolds and ropes (Figure  4 c–f). [ 26–29 ] 
The geometries of topographical features such as ridge height, 
width, inter-ridge distance, diameter of aligned fi bers and width 
of patterned ECM proteins dramatically infl uence growth cone 
behavior. [ 25,30,31 ] Fine-tuning these geometries can enhance neu-
rite alignment and outgrowth such as that seen on increasingly 
smaller diameter (500-5 µm) aligned polymer fi bers. [ 32 ] 
 A wide variety of NRC luminal fi llers have been investigated 
in vivo and often showed considerably enhanced performance 
compared to traditional hollow lumen NRCs. Experimental 
luminal fi llers frequently consist of gels or sponges supple-
mented with ECM proteins and growth factors, supportive cells 
such as Schwann cells, or longitudinal contact guidance cues 
Adv. Healthcare Mater. 2016, 5, 1253–1271
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 Figure 2.  Regeneration of a non-critical length nerve defect (<1 cm in 
rodents) through a traditional hollow lumen NRC. a) The conduit fi lls 
with extracellular fl uids b) A fi brin cable forms connecting the two nerve 
stumps and provides a bridge for cellular migration c) Schwann cells 
form the bands of Büngner and axon regeneration proceeds across the 
lesion. Reproduced with permission. [ 19 ] Copyright 1998, Elsevier.
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such as aligned textures, fi laments, rods, and channels. These 
intra-luminal scaffolds and matrices increase the surface area 
for cellular migration, augment the availability and presenta-
tion of growth instructive molecules, and have been shown to 
improve the directional organization of axons towards the distal 
nerve stump. [ 33 ] 
 Aligned electrospun fi bers have proven to be especially pop-
ular for enhancing anisotropic axonal growth. [ 34,35 ] Electrospun 
fi bers of tuneable diameters can be generated from natural 
or synthetic materials. Synthetic polymers of poly(α-hydroxy 
esters) are commonly used owing to their FDA approved status, 
biocompatibility and adjustable degradation profi les. [ 36 ] A par-
ticularly impressive repair of an eighty millimetre lesion of the 
canine peroneal nerve was achieved using laminin coated col-
lagen-electrospun fi bers. [ 37 ] 
 Advances in a variety of techniques such as 3D-printing, 
self-assembling scaffolds and photolithography offer the 
ability to construct conduits with precise 3D micro-structures 
for enhancing organized axon growth. [ 24 ] For example, Owens 
et al. used bioprinting to generate nerve conduits made from 
multicellular cylinders whilst Georgiou et al. generated aligned 
Schwann cell conduits using tethered collagen gels. Both grafts 
showed potential for repairing rat peripheral nerve lesions. [ 29,38 ] 
 4.1.2.  Application of CNTs 
 CNTs can be used to generate different types of 2D and 3D 
scaffolds with sub-cellular textures similar to ECM fi bers. With 
the added benefi ts of exceptional strength, 
electrical conductivity and capabilities for sur-
face functionalisation, CNT scaffolds could 
provide a superior material for directing and 
enhancing axonal growth within next genera-
tion NRCs. 
 Mattson et al. (2000) were the fi rst to grow 
neurons on CNT substrates and suggested 
their use as a tool to investigate the mecha-
nisms that govern neurite outgrowth at the 
nanometre scale. [ 39 ] Since then, interest 
in CNT substrates to support and control 
neuronal growth, to study neuronal net-
work formation and for coating electrodes 
for interfacing neurological prosthesis has 
increased rapidly. 
 Although to date the application of CNT 
containing scaffolds for nerve repair in 
vivo has been limited, a variety of neuronal 
cell types have been grown on CNT sub-
strates in vitro enabling assessment of their 
biocompatibility and growth promoting prop-
erties. Over 100 studies have reported that 
CNT scaffolds are capable of supporting neu-
ronal survival, growth and maturation. Hip-
pocampal, dorsal root ganglia (DRG), cortical, 
cerebellar neurons as well as the neuron-like 
PC-12, NG108, Neuro2a, and SH-SY5Y cell 
lines, have all been grown on different CNT 
substrate confi gurations. [ 40–46 ] 
 In addition to providing a permissive substrate for neuronal 
growth, patterned CNT substrates are also able to control the 
direction of neurite outgrowth. [ 47–49 ] Zhang et al. reported 
directed neurite outgrowth of the H19-7 hippocampal cell line 
by poly  L -lysine (PLL) coated multi-walled carbon nanotube 
(MWCNT) arrays (Figure  4 c). Alignment of neurites with the 
CNT patterns was dependent on the height of CNT arrays with 
taller arrays (10 µm) performing better than shorter (500 nm) 
arrays. [ 40 ] Human mesenchymal stem cells induced to undergo 
neuron-like differentiation, grew on patterned MWCNT sheets 
with cell bodies and neurite-like extensions orientated along 
the MWCNT in the sheets. [ 50 ] When compared to bare glass 
as a control, the MWNCT sheets signifi cantly upregulated 
the expression of the ß1-integrin receptor, a cell adhesion 
protein. [ 50 ] 
 Patterned CNT substrates have provided a useful tool for 
controlling neuronal adhesion in studies of in vitro neuronal 
network formation. Controlled deposition of CNTs on quartz 
(SiO 2 ) substrates provided islands of adhesive growth surfaces 
allowing precise control over the formation of interconnected 
self-organising neural networks. [ 51,52 ] Scanning electron micro-
graphs revealed that the entanglement of neurites and growth 
cone processes may be an important mechanical mecha-
nism that enables neurons to adhere and migrate on CNT 
substrates. [ 45,53 ] 
 Collectively, these studies highlight the potential of CNTs as 
biomaterials in the repair of damaged neural tissue. Particularly 
promising for applications in NRCs are studies employing ani-
sotropic 3D CNT scaffolds such as CNT yarns, ropes or aligned 
Adv. Healthcare Mater. 2016, 5, 1253–1271
www.advhealthmat.de
www.MaterialsViews.com
 Figure 3.  Examples of CNT surface modifi cations a) derivatization of sidewall defects formed 
via oxidation b) sidewall functionalization via 1,3-Dipolar addition of azomethine ylides c) pol-
ymer wrapping d) internalization of molecules within the CNT lumen e) π-stacking of aromatic 
molecules such as pyrene.
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electrospun CNT composite fi bers. Fan et al. developed super-
aligned poly  D -lysine (PDL) coated MWCNT yarns that provided 
excellent directional guidance to regenerating rat hippocampal 
neurites with minimal neurite branching (Figure  4 d). [ 54 ] A 
similar study reported pristine MWCNT yarns that supported 
the migration of fi broblasts, Schwann cells and directed neurite 
outgrowth from murine DRG explants along the longitudinal 
orientation of the yarn. [ 46 ] MWCNTs yarns can also be knitted 
together in a variety of confi gurations to form novel scaffolds, 
for example, Edwards et al. knitted a 9-ply tubular scaffold 
(Figure  4 e). [ 55 ] CNT yarns can also be wound into large rope-
like structures capable of directing neurite outgrowth. Neural 
stem cells (NSCs) grown on a 1-mm CNT rope differentiated in 
a similar manner to control NSCs on tissue culture polystyrene 
(TCP). The NSCs survived for up to three weeks and neurite 
extension favoured the direction of the CNT fi bers spiralling 
around the rope structure (Figure  4 f). [ 56 ] 
 CNTs can also be incorporated into electrospun polymer 
fi bers either by blending with the polymer solution during 
the electrospinning process so that the CNTs are embedded 
within the fi bers, or by coating the surface of already spun 
fi bers. Kabiri et al. generated poly(L-lactic acid) (PLLA) electro-
spun fi bers blended with either single-walled carbon nanotubes 
(SWCNTs) or MWCNTs. Poor adherence of mouse embryonic 
stem cells to both the MWCNT and SWCNT-PLLA fi bers was 
attributed to their surface hydrophobicity. After oxygen plasma 
treatment, CNT-PLLA fi bers promoted neural differentiation 
and cell growth was aligned along the orientation of the fi bers. 
Cell attachment was comparable to that on PLLA only fi bers. [ 57 ] 
 Whilst data from these preliminary studies are promising, 
confl icting reports of reduced neuronal viability and growth on 
CNTs raises uncertainty as to the suitability of CNT scaffolds 
for enhancing axon growth in NRCs. [ 43,58–63 ] For example, Hu 
et al. compared the growth of postnatal hippocampal neurons 
on nonfunctionalised MWCNTs with that on polyethylenimine 
(PEI) coated onto glass coverslips as the control substrate. [ 64 ] 
They reported that neurite growth parameters including the 
number of neurites per neuron, the total neurite length per 
neuron and neurite branching were substantially reduced on 
the as-prepared (nonfunctionalised) MWCNT substrates com-
pared to growth on PEI. However, no signifi cant differences 
in the average length of individual neurites extended on PEI 
compared to those on the as-prepared MWCNTs were observed. 
This suggests that the as-prepared MWCNT substrates reduced 
the initiation and branching of neurites resulting in a reduction 
in total neurite area, but once initiated, the length of neurites 
compared to control was unaffected. 
 To explore the relationship between MWCNT surface 
charge and neurite outgrowth physiology, Hu et al. compared 
the growth of hippocampal neurons on MWCNTs modifi ed 
Adv. Healthcare Mater. 2016, 5, 1253–1271
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 Figure 4.  Neurite outgrowth directed by contact guidance cues on a) nano imprinted groves and ridges, b) electrospun fi bers, c) MWCNT arrays, 
d) CNT yarns, and f) CNT ropes. a, c and f – are scanning electron micrographs. b and d are immunofl uorescent micrographs. e) Knitted 9-ply CNT 
tubular scaffold. Reproduced with permission. [ 56 ] Copyright 2012, Johns Wiley and Sons. Reproduced with permission. [ 40 ] Copyright 2005, Elsevier. 
Reproduced with permission. [ 55 ] Copyright 2009, Elsevier. Reproduced with permission. [ 199 ] Copyright 2006, Elsevier. Reproduced with permission. [ 200 ] 
Copyright 2005, Elsevier. Reproduced with permission. [ 54 ] Copyright 2012, American Chemical Society.
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with functional groups bearing differing charges including 
poly m-aminobenzene sulfonic acid (zwitterionic), ethylen-
ediamine (+ve), and carboxylic acid (-ve). Intriguingly, the 
positively charge MWCNT substrate enhanced the number of 
growth cones generated, neurite branching and neurite length 
compared to the negatively charged and zwitterionic MWCNT 
substrates, but was still substantially inferior to growth on PEI 
coated coverslips. [ 64 ] 
 Hu et al. subsequently compared neuronal growth on 
PEI-coated glass coverslips with that on either unmodifi ed 
MWCNTs or SWCNTs covalently functionalised with positively 
charged PEI to assess whether PEI functionalization could 
rescue the reduced neurite growth observed on unmodifi ed 
CNTs. [ 65 ] All neurite growth parameters measured including 
average neurite length were signifi cantly reduced on unmodi-
fi ed MWCNTs compared to PEI-coated glass coverslips as pre-
viously observed. Neurite growth on PEI-SWCNTs was superior 
to that on unmodifi ed MWCNTs with an increase in neurite 
branching and slight improvements in neurite length however, 
the number of growth cones and neurites per neuron were not 
different from unmodifi ed MWCNTs, and neurite growth on 
PEI-SWCNTs was still inferior to PEI-coated coverslips. 
 In a recent similar study, embryonic hippocampal neurons 
were grown on a set of MWCNTs (MWCNT-A 0 -A 5 ) chemically 
functionalised covalently or non-covalently to assess the effect 
of functionalisation on neuronal growth. [ 66 ] MWCNT-A 1 -A 5 
were all prepared from raw MWCNT-A 0 that was initially coated 
onto silicon wafer. MWCNT-A 1 -A 3 were non-covalently func-
tionalised with trimethyl-(2-oxo-2-pyren-1-yl-ethyl)-ammonium 
(positively charged), 1-pyrenebutyric acid (negatively charged) 
and pyrene–PEG 5000 , respectively. After oxygen plasma-treat-
ment, MWCNT-A 4 became functionalised with carboxyl, car-
bonyl and hydroxide groups while MWCNT-A 5 was additionally 
covalently functionalised with PEG 5000 . PDL served as control 
in this study. 
 Compared to PDL coated on glass coverslips, all of the func-
tionalised-MWCNT substrates had substantially fewer cells per 
unit area, except for MWCNT-A 4 that supported similar cell 
densities as the control. Neuronal growth differed dramati-
cally on the different functionalised-MWCNTs with neurons on 
MWCNT-A 4 possessing similar length and number of neurites 
to the PDL control whilst neurons grown on MWCNT-A 1 -A 3 
possessed shorter and fewer neurites. Neurites were often 
absent on MWCNT-A 5 . After eight days in vitro (DIV), neurons 
on MWCNTs -A 0 – A 3 aggregated to form clusters and many 
neurites were organized into fascicles, whilst on MWCNT-A 4 
growth of neurons and neurites remained dispersed, similar 
to the PDL control substrate. This suggests that MWCNT sub-
strates A 0 -A 3 promoted greater cell-cell interactions over cell-
substrate interactions. Conversely, cell-substrate interactions 
appeared to be favored on MWCNT-A 4 . Clearly, neuronal adhe-
sion and neurite growth on functionalised-CNT substrates can 
be highly variable and greatly infl uenced by surface coating and 
functionalisation state. 
 For applications in PNR it is not suffi cient that a scaf-
fold simply permits axonal growth. Importantly, the rate of 
axonal growth should also be maximised to minimise lesion 
repair time and improve the probability of functional recovery. 
CNT scaffolds must therefore enable rapid and effi cient axon 
elongation comparable or superior to axon growth through 
the gold standard autologous nerve graft. When assessing the 
suitability of functionalised CNT scaffolds in vitro, careful con-
sideration must be given to control substrates for comparison. 
Glass coverslips and TCP coated with polyamines such as PDL, 
PLL, PEI and poly ornithine have been extensively used as con-
trol substrates when neurite outgrowth has been assessed on 
CNTs. [ 43,46,47,64,66 ] Polyamines are commonly used for coating 
culture surfaces to enhance cellular adhesion through interac-
tions with negatively charged groups on cell surfaces. [ 67 ] These 
coatings have the capacity to support neuronal adhesion, neu-
rite outgrowth and maturation however, for evaluating the 
ability of a biomaterial to support rapid and extensive neurite 
outgrowth for applications in PNR, a superior benchmark 
should be sought such as extracellular matrix proteins with 
known neurite outgrowth promoting properties. 
 Laminin is a heterotrimeric glycoprotein that, along with col-
lagen type IV and fi bronectin constitutes a major component 
of the basement membrane. Laminin is pivotal to the process 
of embryonic neuronal wiring, defi ning migratory and axonal 
pathways. [ 68 ] It is present in all tissues that support axon growth 
in the regenerating adult nervous system such as the olfactory 
pathway; blocking its function via anti-sera signifi cantly impairs 
regeneration. [ 69–71 ] 
 Laminin is consistently reported to be a potent stimulator 
of neurite outgrowth and when directly compared with poly-
amine coated substrates, growth of neurons on laminin is sig-
nifi cantly enhanced, especially for peripheral neurons. [ 68,72–77 ] 
It is often blended or coated onto biomaterials developed for 
nerve regeneration and consistently boosts biomaterial perfor-
mance. [ 32,78,79 ] To evaluate the relative effi cacy of anisotropic 
CNT scaffolds and similar nanomaterials in supporting the 
guidance and regeneration of peripheral axons, it is essential 
that scaffold performance should at the very least be compared 
to well-characterised and physiologically relevant substrates 
such as laminin. 
 Compared to laminin, neurite outgrowth on CNT substrates 
is poor. [ 58 ] However, functionalising CNTs with laminin can 
support substantially greater neurite outgrowth compared to 
laminin-coated TCP or other laminin coated biomaterial con-
trols. [ 80,81 ] CNT/chitosan blended electrospun fi bers provided 
a poor substrate for the adhesion of PC-12 cells compared to 
chitosan fi bers and laminin coated TCP. However, after oxygen 
plasma-treatment and coating with laminin, PC-12 adhesion 
onto CNT containing fi bers increased 20-fold and was report-
edly almost double that on laminin-TCP or chitosan sub-
strates. [ 81 ] Neurite projections followed the orientation of the 
fi bers regardless of fi ber diameter that ranged from 54–284 µm. 
 Electrospun poly (L-lactic acid-co-caprolactone) (PLCL) fi bers 
coated with water soluble MWCNTs, PLL and laminin, directed 
neurite outgrowth from rat DRG neurons along the longitu-
dinal axis of the fi bers, signifi cantly enhancing neurite length 
compared to PLL/laminin coated PLCL fi bers without CNTs. 
These MWCNT coated fi bers also enhanced the expression 
of focal adhesion kinase (FAK) in nerve growth factor (NGF) 
differentiated PC-12 cells. FAK is a key cytoplasmic enzyme 
that mediates the signal transduction pathways of the integrin 
family of laminin cell surface receptors. [ 80 ] Collectively, these 
studies show that with the appropriate surface treatment CNTs 
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can signifi cantly improve neuronal attachment and neurite out-
growth over laminin as a control reference substrate. 
 In vivo evidence of the effi cacy of CNT coated fi bers in pro-
moting nerve regeneration as luminal fi llers in NRCs comes 
from the recent study of Ahn et al. [ 82 ] They covalently linked 
aminated CNTs onto the surface of aligned phosphate glass 
fi bers (PGFs). Their in vitro studies showed that after coating 
with PDL and laminin, the CNT-PGFs supported the attach-
ment and growth of mouse DRG neurons. The growth of these 
neurons on the CNT-PGFs was comparable to that on laminin. 
Both PGFs and CNT-PGFs appeared to align neurites along the 
longitudinal axis of the fi bers. Interestingly, DRG neurites were 
signifi cantly longer on the CNT-PGFs compared to PGFs alone. 
 Bundles of these fi bers were then wrapped within an aligned 
electrospun nanofi ber mat, inserted into a porous poly ( L / D -
lactic acid) nerve repair conduit and used to repair a 10 mm 
rat sciatic nerve lesion. After 16 weeks, the CNT-PGF conduits 
signifi cantly enhanced both the number of regenerating SMI32 
positive axons in the distal nerve stump and functional recovery 
of reinnervated gastrocnemius muscle. However, the perfor-
mance of the CNT-PGF conduit was substantially inferior to 
autologous nerve grafts. Despite the reduced effi cacy compared 
to autografts, attributed to the suboptimal interspacing between 
the PGFs within the NRC; this study demonstrates the feasi-
bility and biocompatibility of CNT tethered biomaterials for 
NRCs. 
 4.2.  CNTs for Mechanical Reinforcement of Biodegradable 
Conduits 
 4.2.1.  The State-of-the-Art 
 It is clear that NRCs composed of biodegradable materials 
provide improved long-term effi cacy over non-degradable 
materials. Although nerve regeneration can proceed through 
non-biodegradable materials such as silicon, these tubes result 
in constriction of the nerve, foreign body reaction, extrusion 
and require a second surgery for removal. [ 83 ] These limita-
tions have resulted in a move away from non-biodegradable 
materials. However, utilising biodegradable materials presents 
another set of obstacles: over time the mechanical properties of 
biodegradable materials inevitably deteriorate and so, the fi ne-
tuning of conduit degradation times is of the upmost impor-
tance to prevent fi brosis and nerve constriction whilst retaining 
suffi cient mechanical strength until regeneration is complete. 
Achieving an appropriate degradation profi le for the repair of 
larger nerve defects is a particularly diffi cult challenge. 
 Naturally occurring biodegradable materials whilst offering 
excellent biocompatibility, often suffer from batch to batch vari-
ability, require extensive purifi cation, degrade rapidly in vivo 
and often have poor mechanical properties. [ 9 ] Synthetic biode-
gradable materials can provide superior mechanical proper-
ties over natural materials however, the degradation of some 
polymers such as polyglycolic acid (PGA) results in the release 
of acidic, cytotoxic by-products reducing their biocompat-
ibility. The strength of natural biomaterials can be signifi cantly 
improved by chemical modifi cations such as cross-linking 
as well as blending or reinforcing with synthetic polymers or 
fi bers. [ 84 ] Innovative fabrication methods can also signifi cantly 
improve structural properties. For example, chitosan conduit 
moulds cast around a tube of braided chitosan yarns possessed 
a tensile strength of 3.69 MPa, 9 times greater than chitosan 
conduits without braided yarns. [ 85 ] Although cross-linking 
enhances the stiffness of hydrogels, excessive cross-linking can 
result in reduced cell migration and proliferation. 
 4.2.2.  Application of CNTs 
 CNTs possess outstanding mechanical properties such as elastic 
modulus of 0.2–1 TPa and strength 200–900 MPa, whilst being 
lightweight and fl exible. [ 86–88 ] Hence, CNTs are already utilised 
in a variety of products such as car bumpers, tennis rackets and 
Kevlar textiles to improve elasticity and strength of the host 
material. [ 89 ] Interest in using CNTs to improve the mechanical 
properties of biomedical materials has increased signifi cantly 
in the last decade with a variety of studies describing the incor-
poration of CNTs with biodegradable polymers, gels and ECM 
proteins. [ 42,84,90–94 ] Although few studies focus on the produc-
tion of CNT-composites specifi cally for NRCs, many studies 
combine CNTs with natural materials and synthetic polymers 
commonly used to fabricate NRCs. 
 4.2.3.  Natural Biomaterials 
 Collagen type I is an essential mechanical and structural 
component of the ECM and is often used for creating tissue-
engineered scaffolds including NRCs. During collagen extrac-
tion and purifi cation natural cross-links between collagen 
fi brils are lost thus, scaffolds produced from purifi ed col-
lagen lack the robust fi ber structure and mechanical stability 
of collagen in situ in the body. Combining collagen scaffolds 
with CNTs increases the static tensile modulus, compressive 
strength and stiffness of the constructs. [ 87,95 ] CNTs enhance the 
mechanical properties of alginate, hyaluronic acid and gelatine 
hydrogels. [ 86,92,96 ] 
 Pure unmodifi ed SWCNTs were incorporated into 3D algi-
nate scaffolds using a freeform multi-nozzle deposition system. 
SWCNT at 1 wt% reinforcement increased the tensile strength 
of alginate struts from 436 to 542 kPa. Cell attachment and pro-
liferation were also improved and attributed to an increase in 
surface roughness on SWCNT containing scaffolds. [ 86 ] Func-
tionalised-SWCNTs incorporated into hyaluronic acid hydrogels 
(0.06 wt% SWCNTs) enhanced the viscoelastic properties of the 
gels reported as a 4-fold increase in storage modulus, without 
signifi cantly affecting their swelling capacity or shear thinning 
behavior. [ 96 ] Gelatin methacrylate coated-CNTs incorporated 
into hydrogels produced 3D scaffolds that were biocompatible 
and possessed enhanced mechanical properties. The compres-
sive modulus of the gel was enhanced from 10 to approximately 
30 kPa whilst still preserving the scaffold porous structure. The 
addition of CNTs also appeared to slow the degradation of the 
scaffolds with an inverse relationship between CNT content 
and the degradation rate reported. CNTs have also been used to 
strengthen fi bers electrospun from chitosan and agarose. [ 81,97,98 ] 
Huang et al. observed that the addition of CNTs to laminin 
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coated chitosan fi bers signifi cantly improved the poor mechan-
ical strength of plain chitosan fi bers making it feasible for their 
application in nerve repair. [ 81 ] 
 4.2.4.  Synthetic Materials 
 Biodegradable aliphatic polyesters are classic synthetic bioma-
terials used for a wide range of tissue engineering and surgical 
products including NRCs. The addition of 1–3 wt% unmodi-
fi ed or functionalised MWCNTs signifi cantly enhanced the 
compressive strength and modulus of poly(lactide-co-glycolide) 
(PLGA) scaffolds. [ 99 ] The MWCNTs were chemically function-
alised with hydroxyl or carboxylic acid groups. Scanning elec-
tron microscopy (SEM) analysis showed these PLGA-MWCNT 
composites supported growth of osteoblast precursors however, 
after 21 DIV, proliferation on the functionalised MWCNT com-
posites was signifi cantly reduced compared to PLGA alone and 
unmodifi ed MWCNT-PLGA composites. Analysis of the in vivo 
biocompatibility of the composites after subcutaneous implan-
tation in adult rats showed initially a minimal infl ammatory 
response similar to the PLGA control, but after four weeks this 
increased to moderate or even severe responses. Infl ammation 
varied between the different functionalised MWCNTs. The for-
mation of a fi brous capsule around the implants was observed 
without systemic or neurological adverse side-effects. 
 Polycaprolactone (PCL) modifi ed with as little as 0.5 wt% 
MWCNTs exhibited signifi cant improvements in tensile and 
compressive modulus and enhanced the proliferation and 
differentiation of rat bone marrow-derived stromal cells. [ 100 ] 
Inclusion of 1 or 3% MWCNTs in PCL hollow fi bers increased 
the tensile modulus of the composite fi bers by 20 and 30%, 
respectively, compared to pure PCL fi bers. An increase in 
MWCNT concentration produced an increase in material stiff-
ness that resulted in a lower elongation to break for compos-
ites containing 3% MWCNTs. [ 61 ] A similar study reported that 
as the concentration of MWCNTs in a polylactide – caprolac-
tone (PLC) composite increased from 2 to 5 wt%, dispersion 
of MWCNTs changed from very uniform to agglomerated 
resulting in greater porosity of the composite and signifi -
cantly reduced tensile strength, perhaps due to poor interfacial 
bonding and poor load transfer at 5 wt% CNT. PLC composites 
with 2 wt% CNT exhibited a 100% increase in elastic modulus, 
a 160% increase in tensile strength and an increase in osteo-
blast viability similar to the data reported by Yildirim et al. in 
2008. The observed improvements in osteoblast viability were 
attributed to the increased surface roughness of the CNT-PLC 
composites. [ 101 ] 
 Incorporation of 0.2 wt% 4-tert-butylphenylene functional-
ised-SWCNTs resulted in extraordinary improvements to the 
mechanical properties of the injectable degradable polymer 
poly(propylene fumarate) for tissue engineering of load bearing 
bones. [ 102 ] MWCNTs at 1–3 wt% in poly(2-hydroxyethylmeth-
acryate), (pHEMA) composites supported growth of neuroblas-
toma cells similar to controls (TCP and unmodifi ed pHEMA) 
whilst 6 wt% MWCNTs in pHEMA resulted in almost complete 
cell death by the seventh DIV suggesting that a fi ne balance 
must be struck between enhancing material mechanical prop-
erties whilst retaining biocompatibility. [ 103 ] 
 4.2.5.  CNT-composite NRCs 
 Preliminary in vivo studies incorporating CNTs into the wall 
of experimental NRCs have also been undertaken. NRCs made 
from electrospun collagen/PCL fi bers containing 0.1% carboxyl-
functionalised MWCNTs showed improved hydrophilicity and 
substantially slower degradation rates compared to collagen/
PCL alone. However, the mechanical strength of the conduit 
was not signifi cantly improved. This was ascribed to insuf-
fi cient dispersion of CNTs within the composite matrix. [ 104 ] 
Despite the lack of improved mechanical properties, MWCNT-
collagen/PCL NRCs supported nerve regeneration in a rat sci-
atic nerve injury model and were found to support Schwann 
cell growth in vitro. Electrophysiological and histological assess-
ment showed that the composite conduits performed better 
then silicon, but were inferior to nerve autografts. Acute infec-
tions, infl ammation or rejection were not observed however, 
the internal surface of the conduit was coated with multi-nucle-
ated giant cells indicating a potential foreign body response. 
 In a similar study using NRCs fabricated from silk fi broin 
containing carboxylated SWCNTs, these NRCs were observed 
to be biocompatible with U373 cells in vitro and supported 
regeneration of the sciatic nerve in a rat injury model. [ 105 ] This 
study did not include an autograft or non-CNT containing silk 
fi broin conduit control making evaluation of effi cacy diffi cult. 
In addition, no information was provided on the infl uence of 
the CNT content on mechanical properties of the conduits. 
 CNTs can clearly enhance the mechanical performance of bio-
materials, particularly the tensile strength however, optimal inte-
gration of CNTs within the composite matrix is vital to ensure 
transfer of mechanical loads and superior mechanical properties 
are attained. [ 89,106,107 ] The poor aqueous solubility of CNTs can 
signifi cantly hinder their homogenous dispersion in aqueous 
solution leading to structural fl aws in the resulting materials 
where aggregates of CNTs have formed. Surface functionalisa-
tion can signifi cantly enhance interactions between CNTs and 
the material matrix improving their integration. [ 87 ] For example, 
collagen gels with 5 wt% albumin-adsorbed on SWCNTs pos-
sessed larger collagen fi brils and increased compressive mod-
ulus than gels with 5 wt% unmodifi ed SWCNTs. Adsorption of 
albumin to SWCNTs clearly improved their dispersion in col-
lagen imparting improved mechanical properties. [ 95 ] 
 CNT reinforcement also appears to slow down the degra-
dation of a surrounding biodegradable matrix which could be 
applied to NRCs for larger defects with longer repair times. [ 92 ] 
Further studies are required to characterise and refi ne the 
biocompatibility and degradation profi les of CNT-composite 
NRCs. Although these limited number of in vivo studies indi-
cate that NRCs containing CNTs are able to repair injuries in 
animal models, whether these conduits offer superior perfor-
mance to equivalent NRCs without CNTs and nerve autografts 
remains to be proven in well-controlled studies. 
 4.3.  CNTs for Electrical Stimulation in NRCs 
 4.3.1.  The State-of-the-Art 
 Although not yet widely adopted in the clinic, studies have 
shown that electrical stimulation via percutaneous or nerve 
Adv. Healthcare Mater. 2016, 5, 1253–1271
www.advhealthmat.de
www.MaterialsViews.com
1262 wileyonlinelibrary.com
P
R
O
G
R
ES
S
 R
EP
O
R
T
© 2016 The Authors. Published by  WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
cuff electrodes can enhance regeneration of injured peripheral 
nerves in animal models and in humans. [ 108,109 ] Designed to 
provoke fi ring of action potentials at physiological rates, elec-
trical stimulation via these techniques can accelerate end organ 
reinnervation and functional recovery by enhancing the number 
of axons that regenerate, by reducing the latency between injury 
and initiation of axon growth and by enhancing the matura-
tion of regenerating fi bers. [ 110,111 ] However, the speed of axon 
growth through the distal nerve once regeneration is initiated 
does not appear to be affected. [ 112 ] The molecular mechanisms 
by which this type of electrical stimulation promotes nerve 
regeneration are not fully understood. Studies have shown an 
enhanced growth state and expression of RAGs such as GAP-
43, neurotrophic growth factors and their receptors are impor-
tant. [ 113–115 ] Carefully designed protocols are required to prevent 
excessive electrical stimulation which can impair nerve cable 
formation and functional recovery. [ 110 ] 
 An alternative method of electrical stimulation makes use 
of weak electrical fi elds and currents, normally below the 
threshold for producing an action potential. Endogenous bio-
electric fi elds regulate many cellular activities including pro-
liferation, migration, and differentiation. [ 116,117 ] Since the early 
1900s, it has been known that weak exogenous electrical stim-
ulation in vitro can affect neuronal growth. [ 113,118 ] Reviewed 
by Ghasemi-Mobarakeh et al., different forms of stimula-
tion have been investigated for their ability to control neurite 
growth including steady direct current (DC) fi elds, magnetic 
fi elds, pulsed electromagnetic fi elds and DC passed through 
conductive growth scaffolds. [ 118,119 ] 
 These studies have shown that electric fi elds can dramatically 
affect the direction of neurite growth, increase neurite initia-
tion, neurite length, neurite branching and the speed of neurite 
growth of primary neurons in vitro. [ 116,120–122 ] Several studies 
investigating the underlying mechanism have implicated the 
induction of an asymmetric distribution of charged receptors on 
the surface of growth cones resulting in an asymmetric response 
to external growth cues and hence, growth cone turning. [ 116 ] The 
effi cacy of DC electrical fi eld stimulation for treating spinal cord 
injury has been investigated in vivo in guinea pigs, dogs and 
humans in a phase I clinical trial. [ 123–125 ] Results have been prom-
ising with return of a variety of functions such as muscle refl exes 
and minor improvements in sensation detection in humans. 
 Electrical stimulation can also exert effects on neurite out-
growth when applied to neurons through conductive growth 
substrates. The use of conductive materials in NRCs would 
enable precise control over the intensity and spatial distribution 
of electrical stimulus delivered directly to regenerating axons. 
As well as direct effects, electrical stimulation can enhance 
the ability of supporting cells to promote axon regeneration. 
Olfactory ensheathing cells (OECs) and Schwann cells cul-
tured on polypyrrole (PPy) composite substrates with electrical 
stimulation upregulated expression of neuronal growth fac-
tors including brain-derived neurotrophic factor (BDNF), NGF, 
vascular endothelial growth factor and neuronal cell adhesion 
molecules such as N-CAM. Concomitantly, the production of 
the growth inhibitory protein, NOGO-A in OECs was reduced 
compared to unstimulated controls. [ 126,127 ] 
 Polyaniline (PANI), PPy, poly(3, 4-ethylenedioxythiophene) 
(PEDOT) and poly(thio-phene) (PT) are the most widely utilised 
conducting polymers for applications in tissue engineering 
and brain machine interfacing. [ 119,128 ] Piezoelectric materials 
such as poly(vinylidene fl uoride) generate transient surface 
charges under material deformation which can also enhance 
process outgrowth in vitro. [ 129 ] To impart conductivity, these 
polymers must be modifi ed through a process known as doping 
resulting in a transfer of charge from dopant molecules to the 
π-conjugated polymer backbone. [ 119 ] 
 These conductive polymers are generally rigid, hard to 
manipulate and non-biodegradable however, by blending with 
biodegradable materials such as chitosan, fl exible and useful 
biomaterials for nerve regeneration can be created. [ 126,130 ] 
Blending with natural polymers such as collagen or the use of 
biologically active dopants such as hyaluronic acid can improve 
their biocompatibility and impart biological functionality. [ 119 ] 
Furthermore, blending with electrospinnable polymers permits 
the production of conductive nanofi bers. These can be used to 
form either NRC walls or aligned structures within the lumen. 
A major disadvantage of this method is a reduction in con-
ductive properties of the resulting blended fi bers compared to 
the pure polymer. However, innovative fabrication techniques 
can overcome this such as core-shell techniques or by simply 
coating the degradable electrospun fi bers with nanometre-thick 
layers of conducting polymer. [ 131 ] 
 PPy has been the most intensely investigated conducting 
polymer for neuroregenerative applications and shows bio-
compatibility with neurons and Schwann cells in vitro and in 
vivo. [ 132 ] Electrical stimulation of neurons on pure PPy and PPy 
composites resulted in signifi cantly longer and more numerous 
neurites then unstimulated controls. [ 131,133–135 ] Enhanced depo-
sition of proteins such as fi bronectin onto PPy during electrical 
stimulation has been shown to contribute to the growth pro-
moting affects. [ 136 ] PPy NRCs have also been used to repair 
peripheral nerves in vivo with a recent study by Xu et al. 
showing effi cacy as good as the gold standard nerve autograft 
for the repair of 10 mm sciatic nerve lesion in rats, although 
it is not clear if electrical stimulation was applied in this 
study. [ 135,136 ] Despite the widely reported positive effects of in 
vitro electrical stimulation on neurite growth, there are limited 
reports of the successful application of conductive NRCs and 
electrical stimulation to enhance peripheral nerve regeneration 
in vivo. This technique has also yet to be trialled successfully 
in the clinic however, development of novel biodegradable and 
biocompatible conducting materials for NRCs continues to be 
an area of research focus. [ 137 ] 
 4.3.2.  Application of CNTs 
 CNTs are excellent conductors of electricity withstanding cur-
rent densities exceeding 10 9 A cm −2 . [ 138 ] SWCNTs can exhibit 
either a semi-conducting or metallic behavior whilst MWCNTs 
are metallic. CNTs are a very attractive material for electrically 
interfacing with neurons on account of their unique combina-
tion of superior electrical conductivity, exceptional strength, 
chemical inertness, high specifi c surface area and fl exibility. 
Recently reviewed by Bareket-Keren et al., a wealth of research 
has been conducted into the suitability of CNTs for stimulating 
and recording neuronal activity. Wang et al. were the fi rst to 
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report the repeated stimulation of primary neurons in vitro 
with a PEG-functionalised CNT pillar array electrode. [ 139 ] Early 
studies focused on the stimulation of neuron-like cells from 
the NG108 cell line, primary rat peripheral and hippocampal 
neurons through CNT fi lms. [ 43,140,141 ] Patch clamping of NG108 
cells grown on CNT fi lms showed normal electrophysiological 
features and electrical excitation upon application of current 
through the CNT substrate. [ 140 ] Stimulation through SWCNTs 
reliably evoked postsynaptic responses in hippocampal neurons 
and with clear potential for electrical coupling with neurons, 
the development of CNT-based electrodes and conductive CNT-
composite materials rapidly followed. [ 141 ] 
 4.3.3.  CNT Electrodes in the Repair of Central Neurons 
 Novel electrodes incorporating CNTs could enable a new gen-
eration of high performance neural prostheses and enhance 
the effi cacy of therapeutic treatments such as deep-brain stim-
ulation. Traditional metal electrodes often suffer from low 
signal to noise ratio, low spatial resolution due to large elec-
trode dimensions, inadequate biocompatibility and induction 
of infl ammatory responses due to a lack of compliance. [ 128 ] 
Smaller electrodes would improve biocompatibility and spatial 
resolution. However, these often suffer from high impedance 
and insuffi cient charge injection. To overcome these signifi -
cant problems, electrodes that can handle larger currents and 
charge densities with high specifi c surface area are required. 
Close physical contact or coupling of electrodes to neurons 
is also important to ensure effi cacy of recording, stimulation 
and to reduce signal-to-noise ratios however, the metallic sur-
face of traditional electrodes does not facilitate cell-material 
interactions. 
 The mechanism of charge injection can greatly affect long-
term performance and biocompatibility of electrodes. Fara-
daic charge injection exhibited by traditional metal electrodes 
including gold, platinum and titanium can result in electro-
chemical products leading to tissue damage and electrode 
degradation. Conversely, capacitive charge injection is not 
associated with electrochemical hazards and is therefore more 
desirable for neuronal interfacing. 
 By coating the surface of traditional electrodes with CNTs 
or CNT composites such as PPy or PEDOT, superior electro-
chemical properties can be achieved. [ 142–144 ] The extremely 
large surface area and electrical conductivity of CNTs enables 
the production of small electrodes whilst retaining high 
charge injection and low impedance. [ 139,142 ] The nanotextured 
surface of CNTs can enhance neural adhesion and neurite 
anchorage improving electrode-neuronal coupling and signal-
to-noise ratio. [ 45,145 ] Due to their capacitive properties, CNTs 
can also safely deliver required charges without electrochemical 
hazards, ideal for neural stimulation. 
 CNT-based electrodes have now been utilised in a variety of 
confi gurations to effectively stimulate neurons in vitro and in 
vivo. [ 142,145 ] During long-term implantation, mismatch between 
the mechanical properties of traditional rigid and non-com-
pliant electrodes and soft nervous tissue leads to tissue damage, 
adverse infl ammation and reduction in electrode effi cacy. Elec-
trode arrays of pure CNTs can be generated on fl exible fi lms for 
compliant implantable neuro-prosthetics. [ 146 ] CNTs can also be 
wet-spun to produce small, soft and fl exible CNT fi ber micro-
electrodes with diameters of 12–43 µm for effective long-term 
in vivo neuronal recording and stimulation. [ 147 ] Vitale et al. 
implanted CNT microfi ber electrodes chronically into Parkin-
sonian rodents and found these to be as effective as larger 
platinum electrodes for alleviating methamphetamine-induced 
rotation via deep brain stimulation. After 6 weeks, histological 
tissue analysis showed that the animals with CNT microfi ber 
electrodes exhibited substantially reduced infl ammation and 
gliosis compared to platinum electrodes. However, the zone 
of neurodegeneration was greater around the CNT electrodes 
compared to platinum controls, attributed to the implantation 
technique. 
 The body of research to date, on CNT-based electrodes, sug-
gests they are capable of safe and effi cient electrical stimulation 
of the nervous system. These properties can also be exploited 
for the development of electrically active biomaterials for appli-
cations in regenerative medicine, including PNR conduits. 
 4.3.4.  Conductive CNT-biomaterial Composites 
 CNTs have been utilised to enhance the electrical properties 
of a variety of synthetic and natural materials, some of which 
could be developed for the electrical stimulation of regenerating 
nerves within NRCs. Several research groups have demon-
strated that dispersion of CNTs in hydrogels such as collagen 
can enhance the electrical properties of the gels whilst retaining 
biological properties and supporting the viability of neuronal 
cells. [ 59,95,148,149 ] McDonald et al. reported that the electrical 
conductivity of collagen-SWCNTs gels increased with rising 
CNT content (0.8–4 wt%). These gels possessed electrical con-
ductivity similar to native human tissue and supported good 
viability and morphology of human dermal fi broblasts cells at 
3 DIV however, after 7 DIV, viability was reduced to 67% in 
the gels with the highest CNT content (4 wt%). [ 149 ] Subsequent 
studies by the same authors have shown that by ensuring good 
dispersion and alignment of CNTs within hydrogels, superior 
electrical percolation can be achieved. Alignment of CNTs, col-
lagen fi brils and seeded cells can be achieved by applying an 
anisotropic mechanical strain to the hydrogels. [ 150 ] 
 In a rare recent study assessing the effi cacy of electrical 
stimulation of nerve growth on conductive CNT composite 
gels, NGF-differentiated PC-12 cells were electrically stimulated 
at 0.1 V for 6 h on a MWCNT-collagen composite. [ 59 ] Results 
showed that the inclusion of MWCNTs improved conductivity 
of the matrix. When the matrix contained 5 wt% MWCNTs, 
neurite length was slightly enhanced over non-stimulated CNT-
collagen controls, but was not improved above non-stimulated 
collagen only controls. Electrical stimulation has also been 
applied to SHSY5Y neuroblastoma cells seeded onto a pHEMA – 
MWCNT hydrogel composite developed for fabricating NRCs. 
The addition of 6 wt% MWCNTs to the pHEMA composite 
improved its conductivity by 11.4-fold. Electrical stimulation 
enhanced SHSY5Y viability however, neurite outgrowth was 
not assessed. 
 As previously discussed, polymer fi bers can be used to fab-
ricate NRCs and intraluminal anisotropic scaffolds. Coating or 
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incorporating CNTs into polymer fi bers can greatly enhance 
their electrical conductivity. [ 151 ] Tethering of carboxylated-CNTs 
to the surface of phosphate glass fi bers enhanced fi ber conduc-
tivity from 10 −13 to 10 −5 through to 10 −6 S cm −1 . [ 82 ] Huang et al. 
generated CNT/chitosan electrospun fi bers and fi lms (5:1 w/v) 
that possessed electrical conductivity of 1.13 × 10 −2 S cm −1 com-
pared to chitosan only (5.7 × 10 −3 S cm −1 ). [ 81 ] The addition of 
CNTs to PLLA electrospun fi bers increased the conductivity of 
MWCNT-PLLA and SWCNT-PLLA composites from 10 −8 and 
10 −9 mS cm −1 to 5 and 6 mS cm −1 , respectively. [ 57 ] 
 Electrical stimulation through CNT ropes and CNT com-
posite fi bers can enhance the differentiation of stem cells 
towards a neural phenotype. PLGA electrospun fi bers were 
vacuum impregnated with SWCNTs and utilised as a substrate 
to enhance the differentiation of induced pluripotent derived 
NSCs. A regimen of 10 min, 30 µA DC electrical stimulation 
markedly increased neuronal differentiation after 14 DIV com-
pared to unstimulated controls. [ 152 ] Electrical stimulation (5 mV, 
0.5 mA, 25 ms) of NSCs grown on CNT ropes also enhanced 
neuronal differentiation and the speed of neurite outgrowth. [ 56 ] 
 Despite the number of studies describing the incorporation 
of CNTs into biomaterials with enhanced electrical conductivity, 
surprisingly few have reported the effect of electrical stimula-
tion via these materials on neurite and axonal outgrowth rates. 
Neurite outgrowth on pure CNT scaffolds subjected to electrical 
stimulation has also been poorly reported. Electrical stimula-
tion of regenerating peripheral nerves through NRCs incorpo-
rating CNTs has yet to be attempted. 
 4.4.  CNTs as Neural Delivery Vehicles 
 4.4.1.  The State-of-the-Art 
 Neurotrophic growth factors such as glial cell line-derived neu-
rotrophic growth factor (GDNF) and the neurotrophins, NGF, 
BDNF and neurotrophin-3 are important secreted proteins that 
support survival and regeneration of peripheral neurons after 
injury. [ 153 ] Unfortunately, the production of these growth fac-
tors declines post-injury and so, for the repair of larger nerve 
lesions and those far from target organs, an exogenous supply 
of growth factors is required to sustain robust axonal growth. 
 The therapeutic application of exogenous growth factors has 
great potential for enhancing PNR. However, there is a need to 
develop delivery methods to maximize the effi cacy of these treat-
ments. Previous studies have shown that uncontrolled release 
of growth factors from NRCs can result in aberrant axonal 
growth and trapping of axons where growth factors become 
concentrated. Excessively high concentrations of growth factors 
can also inhibit Schwann cell maturation preventing normal 
myelination of regenerated axons. [ 154 ] To improve performance, 
methods of controlled release to sustain long-term therapeutic 
action, to prevent the “sweet shop” phenomena and to orches-
trate unidirectional axonal growth are required. 
 A variety of different delivery methods have been investigated 
with the most common involving encapsulation of growth fac-
tors within biodegradable scaffolds and matrices such as gels, 
sponges, electrospun fi bers and polymer rods. [ 155,156 ] These 
techniques often rely on the release of growth factors by passive 
diffusion as the supporting matrix degrades. Further control 
can be achieved by including methods of sequestering growth 
factors within the encapsulating matrix. One such method 
exploits the heparin-binding affi nity of growth factors for reten-
tion on heparin cross-linked within a fi brin matrix. [ 157 ] Using 
this technique growth factor release is controlled by cellular 
activity enabling delivery to be concurrent with the progression 
of cell migration and regeneration through the conduit. This 
method signifi cantly improves nerve regeneration in vivo over 
diffusion-based delivery techniques. [ 158,159 ] 
 An assortment of engineered nanoparticles is currently 
in development with potential to revolutionize the delivery of 
therapeutic agents. Reviewed in detail by GhoshMitra et al. and 
Shi et al., these nanocarriers or nanovectors can provide tissue 
or cell specifi c delivery of precise doses of therapeutics through 
the use of targeting ligands. In the future they could enable 
control of drug delivery via external stimuli such as tempera-
ture, electric or magnetic fi elds. [ 160–162 ] 
 The delivery of growth factors via engineered nanoparticles 
could provide a mechanism for directing axonal outgrowth 
from regenerating nerves towards desired targets. For example, 
magnetic hematite nanotubes functionalised with NGF stimu-
lated neurite outgrowth from PC-12 cells in vitro, with growth 
cones observed extending towards the nanotubes. [ 163 ] Using 
carefully designed magnetic fi elds, movement of the magnetic 
nanotubes could be controlled to direct neurite growth. 
 As an alternative to direct delivery of growth factors, genetic 
manipulation via viral vector mediated gene transfer can be 
utilised to induce growth factor expression either by injec-
tion directly into injured nerves or in therapeutic cells ex vivo 
for subsequent transplantation to the site of injury. [ 154,164,165 ] 
Genetic manipulation using viral vectors to enhance PNR has 
predominantly focused on inducing expression of growth fac-
tors. However, these vectors also present additional opportuni-
ties to manipulate numerous potential therapeutic targets such 
as: prolonging the expression of intrinsic RAGs within neu-
rons; preventing atrophy of denervated muscles, and enhancing 
expression of pro-regenerative proteins in Schwann cells. [ 166 ] 
Developments in viral vector technology have enabled greater 
control over the temporal and spatial expression of targeted 
genes. [ 166 ] Expression can be targeted to specifi c components of 
the peripheral nerve such as Schwann cells, fi broblasts and neu-
rons themselves. [ 167 ] Adeno-associated viral (AAV) vectors offer 
improved effi ciency of gene transfer and longevity of expres-
sion. An AAV-vector based gene therapy, Glybera, has recently 
been approved by the European Medicines Agency demon-
strating the clinical applicability of this delivery technique. 
 4.4.2.  Application of CNTs 
 CNTs are highly amenable to development as drug delivery 
vehicles owing to an exceptionally large specifi c surface area 
and ability to load with therapeutic molecules through a variety 
of different methods. Biomolecules can be attached to CNTs via 
a wide range of permanent or cleavable, covalent or non-cova-
lent surface modifi cations, or by encapsulation of biomolecules 
within the nanotube internal cavity (Figure  3 ). [ 168 ] CNTs can be 
modifi ed with single or multiple molecules enabling multiple 
functionalities. These can include tracking agents such as 
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radioactive particles, magnetic particles, fl uorescent probes, or 
targeting agents such as antibodies and other ligand binding 
molecules. [ 169,170 ] The high aspect ratio of CNTs confers needle-
like properties enabling them to penetrate cell membranes for 
direct translocation into cells. [ 171 ] CNTs can also be internalised 
via receptor-mediated and energy-dependent endocytosis. [ 172 ] 
 Research is currently underway to develop CNTs as delivery 
vehicles for a range of applications. Reviewed extensively by 
Wong et al. in 2013 these include delivery of anti-cancer drugs 
such as topoisomerase inhibitors and non-cancer related drugs 
such as anti-microbials, anti-infl ammatories, anti-hypertensives 
among many others. [ 173,174 ] Varying degrees of success have 
been reported with CNT-based delivery systems. The majority 
of in vitro studies show CNT-biomolecule conjugates enhance 
cellular uptake and can reduce toxicity compared to the respec-
tive free drugs. The number of in vivo studies is limited, but 
nonetheless also demonstrate improved therapeutic effi cacy 
and reduced toxicity in mice. [ 175 ] However, demonstration of 
their effi cacy compared to other nanoparticulate delivery sys-
tems has not been undertaken and some studies have reported 
poor control over drug release. [ 176 ] 
 CNTs can be internalised by neurons, astrocytes and micro-
glia, and by altering surface functionalization, uptake by neu-
rons is preferentially enhanced. [ 177,178 ] As an alternative to viral 
vectors, CNTs have potential for therapeutic gene and short 
interfering RNA delivery. Encouraging results have already 
been achieved for enhancing neuroprotection after stroke by 
caspase-3 silencing however, applications in PNR have so far 
received little attention. [ 174 ] Preliminary in vitro studies have 
shown CNTs can be used to deliver and to enhance the thera-
peutic effects of neural growth factors in peripheral neurons. 
MWCNTs covalently functionalised with NGF and BDNF pro-
moted neurite outgrowth of cultured embryonic chick DRG 
neurons similar to soluble NGF and BDNF. [ 179 ] Further inves-
tigation revealed water soluble CNTs amplifi ed the neurite 
outgrowth promoting effects of soluble NGF via activation of 
the ERK signalling pathway and upregulation of neurotrophin 
receptors TrkA and p75 NTR . [ 180,181 ] 
 MWCNTs have also been conjugated to the neurite out-
growth promoting peptide sequences  L -arginine-glycine- L -
aspartic acid (RGD) and isoleucine-lysine-valine-alanine-valine 
(IKVAV). [ 182 ] As well as neurite outgrowth, these peptide 
components of fi bronectin and laminin, promote cell adhe-
sion, migration and proliferation by interaction with integrin 
receptors. [ 183 ] The MWCNT-peptide conjugates were found to 
be biocompatible when dispersed in culture media with no 
reported deleterious effects on the viability, morphology or 
function of dissociated rat hippocampal neurons. The conju-
gates were also non-immunogenic after intraperitoneal injec-
tion into albino (BALB/c) mice. Further experiments to assess 
the ability of these CNT-conjugates to enhance neurite out-
growth in an anisotropic scaffold would be very interesting. 
Collectively, these studies suggest that there may be signifi -
cant potential for CNT-based delivery systems within NRCs 
however, the conjugation of CNTs with therapeutic biomol-
ecules for enhancing nervous system regeneration has been 
limited and more studies investigating the neurite outgrowth 
promoting properties of CNTs conjugated to axon guidance 
molecules are essential. 
 Many studies have primarily focused on developing bio-
compatible CNTs with simple surface modifi cations often 
consisting of carboxylated, aminated, PEGylated or poly-
amine conjugated CNTs. Reviewed recently by Hwang et al., 
these modifi cations have however, produced some interesting 
effects and show potential for PNR. [ 184 ] Exposing cultures of 
hippocampal neurons to water soluble PEG-functionalised 
SWCNTs reduced the number of neurites whilst simultane-
ously increasing their length. [ 185 ] Subsequent studies sug-
gested that neurite outgrowth was increased due to blockade 
of endocytosis and changes in calcium dynamics by the PEG-
SWCNTs. [ 186,187 ] Treatment of spinal cord transected rats with 
PEG-SWCNTs increased the number of nerve fi bers regener-
ating into the lesion, signifi cantly reduced lesion volume and 
moderately improved behavioral recovery without causing 
toxicity or inducing gliosis. Despite these encouraging studies 
concerns about CNT toxicity and long-term affects after inter-
nalisation prevail. Using CNTs to deliver biomolecules to the 
surface of cells only without internalisation of the nanotube 
could reduce toxicity. This could be achieved within NRCs by 
utilising long CNT yarns or ropes. In this confi guration CNTs 
could facilitate the spatially controlled delivery of axon guid-
ance molecules for directing growth cone migration through 
NRCs as discussed in section  4.1 . 
 5.  Issues of Biocompatibility and Future 
Perspectives 
 Several issues currently impede the development of CNT-based 
biomaterials. Variability in CNT manufacture and surface mod-
ifi cation can lead to batches possessing different quantities of 
impurities, morphological, structural and chemical characteris-
tics, all of which signifi cantly impact on toxicity, pharmacoki-
netics and functionality. In the future, producing a consistent 
product will be vital for clinical licensing. Reviewed recently by 
Zhao et al., the assessment of CNT toxicity has been particularly 
challenging. [ 188 ] Over the past 15 years an array of in vivo and 
in vitro studies have provided confl icting and highly variable 
accounts of toxicity and infl ammation, often attributed to dif-
ferences in experimental methodology, CNT properties such as 
solubility and confounding metal catalyst or amorphous carbon 
impurities in samples. CNTs must be purifi ed to remove these 
toxic contaminants shown to produce reactive oxygen species 
and induce oxidative stress. [ 189 ] Surface functionalisation to 
improve CNT solubility and dispersal also reduces toxicity. [ 190 ] 
 Of crucial importance, several research groups have investi-
gated the long-term in vivo fate of CNTs, again with variable 
results. The morphological characteristics and surface func-
tionalisation of CNTs can signifi cantly affect pharmacoki-
netics. Intravenously administered pristine SWCNTs, tracked 
by isotope ratio mass spectroscopy, showed high uptake in 
the lungs, liver, and spleen without apparent excretion within 
28 days however; surface modifi cation such as PEG-function-
alisation increased the circulation time in blood, reduced 
retention within reticuloendothelial systems and accelerated 
excretion. [ 191–193 ] 
 CNT length also determines clearance rates with longer 
CNTs persisting as aggregates whilst shorter nanotubes are 
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more easily phagocytosed and cleared through different excre-
tory pathways. [ 189 ] An in depth discussion of the toxicity of 
CNTs is beyond the scope of this review however, it is clear 
that each type of functionalised CNT engineered for biomed-
ical applications will exhibit unique properties and require 
individual toxicological assessment appropriate to the mode of 
administration. 
 The slow progress of PNR will require CNT containing 
NRCs to exhibit long-term biocompatibility with minimal 
infl ammation or fi brosis throughout regeneration, occurring 
over months to years. CNTs could be incorporated into NRCs 
in a variety of ways that will affect their long-term biocompat-
ibility and persistence. They may be short and dispersed within 
a biodegradable gel or polymer matrix, or used to coat surfaces. 
On degradation of the matrix, CNTs will become available for 
cellular uptake and may cause unintended effects. Whether 
they persist within the nerve or are removed and degraded by 
phagocytic cells is not yet clear. 
 CNTs can be biodegraded within neutrophils and to a lesser 
extent within macrophages however, this is highly infl uenced by 
the number of CNT walls i.e., single or multi-walled, and the 
extent of surface functionalization. [ 194–196 ] Gradual internalisa-
tion and accumulation of short CNTs into peripheral neurons 
over years and decades, as well as translocation to the spinal cord 
could lead to deleterious effects and should not be overlooked. 
 Long CNT ropes and yarns are not biodegradable and will 
therefore be retained within the nerve tissue indefi nitely. This 
may prevent unwanted effects associated with cellular CNT 
internalisation. However, to what extent CNTs will elicit a 
problematic foreign body response is unclear. A two-year his-
tological study investigating the biopersistence of oxidised 
MWCNTs after subcutaneous implantation showed that large 
CNT agglomerates (>5 µm) remained within the intercellular 
space, became surrounded by granulation tissue consisting of 
fi broblasts and foreign body giant cells, whilst smaller aggre-
gates (<5 mm) were taken up by macrophages, internalised into 
lysosomes, but only partially degraded. No severe infl ammatory 
changes such as necrosis or carcinogenesis were reported. After 
2 years a thin layer of fi brous connective tissue surrounded the 
MWCNTs. The authors concluded that the MWCNTs were bio-
compatible and suitable for use in medical devices. [ 197 ] Other 
studies have also reported minimal infl ammatory response to 
CNT implantation. [ 147 ] These studies are promising for the long-
term biocompatibility of CNT containing implants however, the 
formation of granulation tissue within the nerve repair pathway 
is of concern and could lead to disorganized axon growth and 
impair functional recovery. 
 In vitro studies have also indicated CNTs can affect neu-
ronal calcium dynamics, inhibit endocytosis, act as potassium 
channel blockers, increase neuronal excitability and provide 
electrical shortcuts, all of which may have implications for 
normal propagation of action potentials. [ 65,185–187,198 ] How the 
presence of CNTs affects normal peripheral nerve function 
requires detailed in vivo investigations. 
 6.  Summary and Conclusions 
 The AxoGen Avance decellurized human nerve allograft 
appears to be the most promising currently available alternative 
to the gold standard nerve graft. Multicenter clinical studies 
have shown Avance allografts are superior to standard col-
lagen conduits and perform similar to autografts in lesions up 
to 5 cm however, further clinical data is needed on their per-
formance for repairing larger lesions (>3 cm). [ 14 ] These grafts 
provide real nerve architecture, extracellular matrix and longi-
tudinal topological guidance through basal lamina endoneurial 
tubes. They are available in a range of diameters and in lengths 
up to 7 cm. These grafts could also be combined with adjunc-
tive therapies such as growth factor supplementation, gene 
therapy and nerve-cuff electrical stimulation. However, the fol-
lowing important factors may limit the widespread use of this 
product. As with any processed human donor tissue, the grafts 
cannot be guaranteed to be free of all pathogens; the availability 
of donated human cadaver nerve material to make the Avance 
grafts could be an issue if demand exceeds supply. Further-
more, substantial nerve injuries such as those of the brachial 
plexus will require longer and/or complex graft shapes beyond 
the structural capacity of Avance grafts. Consequently, in the 
long-term, next generation NRCs will likely be the ideal treat-
ment option for complex PNR. 
 Enhancing the performance of peripheral NRCs is an ever 
expanding intense fi eld of research with an extensive range 
of biomaterials and cutting-edge technologies available to the 
tissue-engineering scientist. We initially proposed the ques-
tion, is there a role for CNTs in repairing peripheral nerves? 
At this stage, the application of CNTs for PNR is in its infancy; 
the full potential of this material is yet to be realised and issues 
of biocompatibility must fi rst be resolved defi nitively. However, 
with such an unusual and desirable combination of properties 
amenable for PNR, it is highly likely CNTs will be utilised in 
future NRCs to enhance their strength, conductivity and axon 
regeneration promoting properties ( Figure  5 ). 
 Whilst current materials used for NRCs such as collagen and 
PGA are suitable for shorter nerve lesions, there is still a need to 
develop materials to enhance the mechanical structure of NRCs 
whilst facilitating precise refi nement of the degradation pro-
fi les of NRCs for larger and more complex nerve lesions. Fiber 
reinforcement is a very common technique used to enhance the 
mechanical properties of materials. CNTs clearly have excellent 
mechanical properties and if incorporated into NRC walls, could 
be an ideal reinforcing material to enhance structural properties 
whilst slowing, but still retaining the biodegradability of the sur-
rounding matrix to limit constriction of the repaired nerve. 
 Although the studies reviewed in section  4.2 provide prom-
ising insights into the application of CNTs for PNR, further 
development of material processing techniques and CNT sur-
face modifi cations are needed to improve the integration of 
CNTs within biomaterial matrices to impart improved mechan-
ical properties to NRCs. A greater understanding of how CNTs 
infl uence degradation profi les of biodegradable materials and 
improved methods for fi ne-tuning biodegradability are also 
essential. CNTs could be incorporated into NRC walls in a con-
centration gradient increasing from proximal to distal. This 
would allow the biodegradation of the NRC to be concurrent 
with the expected rate of regeneration from the proximal to the 
distal nerve stump and limit constriction of the proximal end 
of the nerve that might otherwise occur in NRCs of uniform 
biodegradability. 
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 Developments in luminal fi llers for NRCs have provided 
techniques and materials to generate a range of longitudinally 
orientated fi laments, fi bers and features for enhancing the ani-
sotropic organization of regenerating axons, a major missing 
feature from current NRCs. Electrospun fi bers have been the 
most popular luminal fi llers to date demonstrating good effi -
cacy in in vivo studies. Combining these fi bers with CNTs could 
enhance the axon growth promoting properties of these fi bers 
further by providing nanoscale surface roughness that can aug-
ment growth cone interactions with the fi bers. CNT coatings 
would also provide a signifi cantly greater surface area for fun-
tionalisation with growth-promoting molecules to directly facili-
tate interactions with migrating growth cones to promote PNR. 
 Although early studies suggested CNTs may not provide a 
good substrate for rapid and extensive neurite regeneration, 
the key to exploiting CNT properties for PNR in the future will 
clearly be to functionalise them with ECM molecules such as 
laminin. [ 58,80,82 ] This concept was successfully demonstrated by 
Jin et al. in 2011, who reported superior neurite outgrowth from 
postnatal peripheral neurons on PLCL electrospun fi bers coated 
with laminin adsorbed CNTs in comparison to PLCL-laminin 
adsorbed fi bers without CNTs. [ 80 ] The mechanism by which 
CNTs stimulate neurite outgrowths is poorly understood and 
requires further investigation. However, the reported increase 
in FAK expression with increase in neurite outgrowth suggests 
that the CNTs enhanced the presentation of laminin to integrin 
receptors owing to the greater surface area imparted by the 
nanotextured CNT layer. This study provides good evidence of 
the feasibility and effi cacy of utilising CNTs to enhance axon 
regeneration in a confi guration directly relevant to in vivo 
NRCs i.e., coated aligned electrospun fi bers as luminal fi llers. 
CNT-functionalisation with laminin and other nerve regenera-
tion relevant ECM proteins may be the way forward in expe-
diting the development of CNT-based PNR in the medium to 
long-term. 
 The cytotoxicity of CNTs is still of major concern in the 
development of CNT-based NRC. The general biocompatibility 
of CNTs with neural tissue, particularly in vivo, is currently 
poorly understood. Establishing whether or not CNTs are bio-
compatible with neural tissue is key to the research efforts 
aimed at exploiting CNTs for PNR. Such studies will likely 
provide key insights leading to the identifi cation of the CNT 
confi gurations that are most suitable for preservation of bio-
compatibility for PNR. The ideal CNT confi guration(s) for PNR 
therefore, requires more research to inform the development of 
CNT-based NRCs. 
 The systemic toxicity of CNTs is also presently a controver-
sial issue and although insights are slowly forthcoming, the 
lack of unequivocal proof of the safety of CNT exposure to 
neural tissue via the circulatory system is a signifi cant hurdle 
to clinical application in NRCs. In response to safety con-
cerns, the FDA Center for Biologics Evaluation and Research 
(CBER) is undertaking its own investigations into the mecha-
nisms of CNT toxicity to blood vessels and blood cells. The 
intense interest in the development of CNTs for a vast array 
of biomedical applications should ensure fi nancial investment 
in overcoming these toxicological issues and advancement of 
CNT-based devices towards clinical trials. 
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 Figure 5.  Schematic illustration of CNT utilisation within PNR conduits. a) schematic showing a CNT non-covalently functionalised with NGF for con-
trolled drug delivery; b-h scanning electron microgaphs of b) CNT rope, scale bar 200 µm c) CNT coated electrospun poly ( L -lactic acid-co-caprolactone) 
nanofi bers, scale bar 5 µm d) CNT yarns, scale bar 50 µm e) CNT-collagen gel, black arrows indicate CNTs, scale bar 100 nm f) strain induced align-
ment of a CNT-collagen gel, white arrow indcates direction of strain g) highly porous CNT – poly (L-lactide) nanocomposite scaffold, scale bar 200 µm 
h) CNT reinforced collagen/poly (ε-caprolactone) electrospun nerve repair conduit, left scale bar 2 µm, right scale bar 100 µm. Reproduced with permis-
sion. [ 54 ] Copyright 2012, American Chemical Society. Reproduced with permission. [ 80 ] Copyright 2011, Elsevier. Reproduced with permission. [ 56,150,201 ] 
Copyright 2005, 2008, 2012, John Wiley and Sons. Reproduced with permission. [ 90,104 ] Copyright 2014 2015, IOP publishing.
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 NRCs must be made, at least in part, from biodegradable 
materials to ensure the regenerating nerve is not constricted. 
Thus, NRCs containing CNTs embedded in biodegradable 
composites could present a risk of systemic exposure to CNTs 
during the degradation process. The use of knitted or long rope-
like CNT scaffolds with retention of CNTs at the site of implan-
tation should circumvent the potential risk of CNT entry into 
the circulatory system. Such scaffolds may therefore initially be 
preferable for development towards clinical trials for complex 
PNR. However, if adverse reactions occur and the CNT device 
required removal, this could cause severe damage to the nerve, 
as the entire length of nerve within the conduit would likely 
require resection. These potentially signifi cant safety risks 
make it unlikely that the initial clinical trials involving CNTs 
will be for development of NRCs for PNR. 
 In the short-term, clinical trials involving CNTs will most 
likely receive approval when the benefi t of using CNTs out-
weighs the risks involved and/or where no other therapies are 
available. For example, end of line treatments for cancer such 
as CNT-based drug delivery vehicles or CNT facilitated tumour 
targeting. Alternatively, approved trials may involve the use of 
implants that contain CNTs, but where the CNTs are encapsu-
lated, unable to distribute systemically, and are easily removed, 
for example, in biosensors or CNT-based electrode arrays. Suc-
cesses in these trials will undoubtedly open doors to the clinical 
application of CNTs in NRCs. 
 The on-going intense research into the application of CNTs 
for complex PNR will likely produce signifi cant insights and 
a comprehensive characterisation of the effi cacy of CNTs in 
nerve repair. This will hopefully inform the design of bespoke 
CNT-based NRCs that can proceed to clinical trials and FDA 
approval in the long-term. 
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